Compare Adobe Systems Inc (ADBE) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs AstraZeneca plc — how do they compare? Adobe Systems Inc trades at $258.28 (market cap $104.82B), while AstraZeneca plc trades at $158.76 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 2.4× Adobe Systems Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | AZN | |
|---|---|---|
Market Cap | $104.82B | $248.14B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $209.48 |
52-Week Low | $193.41 | $147.06 |
Enterprise Value | $106.26B | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $263.71, down 3.39% on the day, with the stock showing mixed technical signals amid a bullish overall trend. Fundamentally, the company demonstrates strong profitability with a 28.69% net income margin and consistent earnings beats, though recent news highlights AI competition concerns. Revenue growth remains robust at $23.77 billion for 2025, while valuation metrics like a P/E of 15.09 appear reasonable relative to historical levels.
The outlook for ADBE is cautiously optimistic with solid fundamentals offset by near-term AI disruption fears. Investment opportunity lies in the company's strong cash flow generation and market leadership, while risks include competitive pressure from AI tools and CEO transition uncertainty. Analyst consensus remains favorable with 49.2% buy ratings, though the stock trades below the $248.86 consensus price target.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
